Erasca and Tango Therapeutics Launch Clinical Collaboration for Combination Cancer Therapy
Summary
Erasca and Tango Therapeutics have announced a clinical collaboration and supply agreement to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat (TNG462). This partnership will support a Phase 1/2 clinical trial targeting patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer, addressing a significant unmet medical need. Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the clinical trial. This collaboration is a material pipeline development for Erasca, expanding the potential clinical utility and market for its key asset, ERAS-0015, through a novel combination approach. Investors will closely watch for initial data from this Phase 1/2 trial, as positive results could significantly de-risk both compounds and validate the dual-targeted strategy.
At the time of this announcement, ERAS was trading at $15.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $1.01 to $15.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.